Tivozanib is an oral selective vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor that is recently approved by the European Medicines Agency for the treatment of previously untreated patients with metastatic renal cell carcinoma (mRCC) as well as for those patients with disease progression during or after cytokine therapy. Nowadays, in first-line and second-line treatment of mRCC, there is an abundance of options, mainly consisting of VEGFR-directed tyrosinekinase inhibitors. This review focusses on the role of tivozanib with respect to patient selection and future perspectives in this fast-changing landscape.

Additional Metadata
Keywords tivozanib, metastatic renal cell cancer, tyrosine kinase inhibitor
Persistent URL dx.doi.org/10.2147/ijnrd.S169056, hdl.handle.net/1765/117073
Journal International Journal of Nephrology and Renovascular Disease
Citation
Rodenburg, R.J, & Eskens, F.A.L.M. (2019). Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives. International Journal of Nephrology and Renovascular Disease, 12, 137–141. doi:10.2147/ijnrd.S169056